Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real‐world clinical practice: Results of a 36‐month post‐marketing surveillance study (J‐STEP/LT)

AIMS/INTRODUCTION: Tofogliflozin is a sodium–glucose cotransporter 2 (SGLT2) inhibitor that lowers plasma glucose levels by enhancing urinary glucose excretion. After its approval in Japan in 2014 for the treatment of type 2 diabetes mellitus, we carried out a 3‐year prospective observational post‐m...

Descripción completa

Detalles Bibliográficos
Autores principales: Utsunomiya, Kazunori, Koshida, Ryusuke, Kakiuchi, Seigo, Senda, Masayuki, Fujii, Shoko, Kurihara, Yuji, Gunji, Ryoji, Kaku, Kohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7858109/
https://www.ncbi.nlm.nih.gov/pubmed/32597517
http://dx.doi.org/10.1111/jdi.13333

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7858109/
https://www.ncbi.nlm.nih.gov/pubmed/32597517
http://dx.doi.org/10.1111/jdi.13333

Ejemplares similares